港股异动 | 中生制药(01177)现涨超5% 创新药罗伐昔替尼片关键注册研究达主要终点

智通财经04-22

智通财经APP获悉，中生制药(01177)现涨超5%，截至发稿，涨4.7%，报2.45港元，成交额2714.65万港元。消息面上，中国生物制药公布，集团自主研发的1类创新药罗伐昔替尼片“Rovadicitinib (TQ05105)”用于治疗中高危骨髓纤维化的关键注册临床研究已达主要终点。集团已与中国国家药品监督管理局药品审评中心(CDE)就TQ05105片的上市申请进行沟通，并获得CDE同意提交...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2429096624?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-22 09:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2429096624","market":"us","top_or_hot":-1,"title":"港股异动 | 中生制药(01177)现涨超5% 创新药罗伐昔替尼片关键注册研究达主要终点","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，中生制药(01177)现涨超5%，截至发稿，涨4.7%，报2.45港元，成交额2714.65万港元。消息面上，中国生物制药公布，集团自主研发的1类创新药罗伐昔替尼片“Rovadicitinib (TQ05105)”用于治疗中高危骨髓纤维化的关键注册临床研究已达主要终点。集团已与中国国家药品监督管理局药品审评中心(CDE)就TQ05105片的上市申请进行沟通，并获得CDE同意提交...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1106277.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 中生制药(01177)现涨超5% 创新药罗伐昔替尼片关键注册研究达主要终点</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 中生制药(01177)现涨超5% 创新药罗伐昔替尼片关键注册研究达主要终点\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-22 09:33 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1106277.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，中生制药(01177)现涨超5%，截至发稿，涨4.7%，报2.45港元，成交额2714.65万港元。消息面上，中国生物制药公布，集团自主研发的1类创新药罗伐昔替尼片“Rovadicitinib (TQ05105)”用于治疗中高危骨髓纤维化的关键注册临床研究已达主要终点。集团已与中国国家药品监督管理局药品审评中心(CDE)就TQ05105片的上市申请进行沟通，并获得CDE同意提交...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1106277.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1106277.html","article_id":"2429096624","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2429096624","pubTimestamp":1713749616,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，中生制药现涨超5%，截至发稿，涨4.7%，报2.45港元，成交额2714.65万港元。消息面上，中国生物制药公布，集团自主研发的1类创新药罗伐昔替尼片“Rovadicitinib ”用于治疗中高危骨髓纤维化的关键注册临床研究已达主要终点。该行相信，这反映中生制药的商业能力得到跨国公司的高度认可。汇丰预计，中生制药在新药上市和业务前景可观支持下得到持续增长。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","YINN":"三倍做多富时中国ETF-Direxion","BK1161":"生物科技","01477":"欧康维视生物-B","06978":"永泰生物-B","01177":"中国生物制药","YANG":"三倍做空富时中国ETF-Direxion","BK1515":"抗疫概念","BK1521":"挪威政府全球养老基金持仓","BK1191":"制药","BK1589":"北水核心资产","07226":"XL二南方恒科","BK1574":"生物医药B类股"},"translate_title":"Hong Kong stocks change Zhongsheng Pharmaceutical (01177) is now up more than 5%, the key registration study of the innovative drug rovaxitinib tablets has reached the main endpoint","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1,"01477":1,"06978":1,"07226":1,"YANG":1,"YINN":1},"content_text":"智通财经APP获悉，中生制药(01177)现涨超5%，截至发稿，涨4.7%，报2.45港元，成交额2714.65万港元。消息面上，中国生物制药公布，集团自主研发的1类创新药罗伐昔替尼片“Rovadicitinib (TQ05105)”用于治疗中高危骨髓纤维化的关键注册临床研究已达主要终点。集团已与中国国家药品监督管理局药品审评中心(CDE)就TQ05105片的上市申请进行沟通，并获得CDE同意提交本品上市申请的意见。集团将于近期递交TQ05105片的上市申请。汇丰此前发布研报称，中生制药与勃林格殷格翰在中国合作开发三个处于临床开发阶段的资产及若干早期临床资产。该行相信，这反映中生制药的商业能力得到跨国公司的高度认可。该行认为，三项资产具有一流潜力，并与集团现有的产品线产生协同效应。该行预计，三个资产Brigimadlin，Zongertinib和BI-764532将分别于2025年、2027年、及2028年在中国上市，并在2030年达到500亿元人民币的销售高峰。汇丰预计，中生制药在新药上市和业务前景可观支持下得到持续增长。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2429096624"}